<DOC>
	<DOCNO>NCT00142129</DOCNO>
	<brief_summary>The purpose study evaluate tumor patient Waldenstrom 's macroglobulinemia respond treatment bortezomib ( Velcade ) see effect ( good bad ) cancer .</brief_summary>
	<brief_title>Bortezomib ( Velcade ) Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- Patients receive bortezomib intravenously twice weekly 2 week day 1,4,8 11 cycle . A 10-day rest period ( day 12-21 ) follow 2 week treatment . The treatment cycle repeat eight time depend upon disease response patient tolerate drug . - The following procedure conduct part treatment monitoring : DAY 1 VISIT ( treatment cycle ) : evaluation disease-related symptom , vital sign weight blood test . DAY 4 VISIT ( treatment cycle ) : vital sign blood work . DAY 8 VISIT ( treatment cycle ) : vital sign blood work . DAY 11 VISIT ( treatment cycle ) : vital sign , blood work , possible CT Scan . - Treatment discontinue follow occur : Disease get bad , severe side-effects patient require anti-cancer therapy . - At end treatment ( 30 day last dose study drug ) patient physical exam , vital sign , evaluation disease-related symptom , blood work CT scan tumor measurement . - Long term follow-up consist every 3 month clinical visit disease progression 2 year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Clinicopathological diagnosis Waldenstrom 's macroglobulinemia fail one first line therapy Measurable disease , define presence immunoglobulin M ( Ig M ) paraprotein minimum IgM level &gt; 2 time ULN Karnofsky performance status &gt; 60 Life expectancy &gt; 3 month Baseline platelet count &gt; 50,000,000,000/L ANC 750,000,000/L AST ALT &lt; 3 x ULN Total bilirubin &lt; 2 x ULN Calculated measure creatinine clearance &gt; 30mL/minute Serum sodium &gt; 130 mmol/L Greater equal Grade 2 peripheral neuropathy Hypersensitivity bortezomib , boron mannitol Prior therapy Velcade Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
</DOC>